Indian government is likely to commission a study soon to assess the impact of foreign direct investment in existing pharmaceutical companies. In recent years, there were spate of FDI in brownfield where global majors have acquired local companies. Now, there is a concern that generic drugs production in India will be affected. With affordable healthcare being a challenge in a poor country, allowing foreign MNC in a strategic sector may lead to monopoly. The market size of the India’s pharma industry is estimated at over $20 billion.